- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02127892
SCID Bu/Flu/ATG Study With T Cell Depletion
Phase I/II Trial of Hematopoietic Stem Cell Transplant (HSCT) for Children With Severe Combined Immune Deficiency (SCID) and Without an HLA-Matched Sibling Donor
Study Overview
Status
Conditions
Detailed Description
The study is being conducted to assess the following:
- overall survival
- event-free survival (events are defined as: death,non-engraftment/2nd transplant, immune reconstitution failure)
- acute toxicity of the conditioning regimen
- engraftment frequency immune reconstitution frequency and tempo acute and chronic graft-versus-host disease (GVHD), frequency and severity.
The outcome from this protocol will be compared to the retrospective cohort consisting of all patients who have undergone haplo-identical HSCT for SCID at CHLA from 1984-2006 based on the assessment of the above-listed endpoints.
The CliniMACS device will be used for CD34+ selection in place of the Isolex 300i. The CliniMACS CD34 Reagent System is an investigational medical device that has not yet been approved by the FDA. This device is used in vitro to select and enrich specific cell populations. When using the CliniMACS CD34 Reagent, the system selects CD34+ cells from heterogenous hematological cell populations for transplantation in cases where this is clinically indicated.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90027
- Children's Hospital Los Angeles
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- All patients with SCID who lack a histocompatible sibling or HLA-matched related donor will be considered as candidates for this study protocol.
Eligible patients must have adequate physical function to tolerate the chemotherapy conditioning regimen and the HSCT, as measure by:
- Renal: creatinine clearance or GFR ≥50 ml/min/1.73m2, and not requiring dialysis
- Pulmonary: Because patients with SCID frequently present with infectious pneumonia causing ventilatory failure, patients will be considered for enrollment in the study even if respiratory failure requiring mechanical ventilatory support is present. In patients recently diagnosed with pneumonia, efforts to stabilize the respiratory status will be made prior to enrollment in the study.
- Infectious disease status. The presence of infection per se will not be a reason for exclusion from the study. Patients with SCID are frequently infected with both routine pathogens as well as opportunistic infections. Antibiotic, antifungal and antiviral prophylaxis and therapy will be instituted as clinically indicated. Despite the use of antimicrobial therapy, the ability to control infections will not be achieved unless HSCT is performed. Therefore, subjects may be enrolled in the study, even though infection is present, because control of infection may depend on engraftment of a donor immune system.
- Patients will be 0-21 years of age.
Exclusion Criteria:
- Patient with histocompatible sibling or other related donor
- End-organ failure that precludes the ability to tolerate the transplant procedure, including conditioning.
- Renal failure requiring dialysis
- Congenital heart disease resulting in congestive heart failure
- Severe CNS disease, e.g., coma or intractable seizures
- Ventilatory failure due to non-infectious etiology
- Major congenital anomalies that adversely affect survival, eg CNS malformations
- Metabolic diseases that would affect transplant survival, eg urea cycle disorders
- HIV infection
Since the only chance of survival for patients with SCID is successful transplantation, all patients with SCID will be considered to be potential subjects for the study, regardless of end-organ dysfunction.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: unrelated BM with T cell depletion
Acceptable matching for matched unrelated donor (MUD) bone marrow will be genotypic matches at 10 of 10 HLA alleles (HLA-A, B, C, DR and DQ) or 9 of 10 HLA alleles.
|
Remaining unmanipulated bone marrow will be processed to isolate CD34+ cells (T cell depleted).
Other Names:
|
Other: unrelated cord blood
Acceptable matching for unrelated cord blood will be a genotypic match at 6 of 6 alleles (HLA A, B and DR) or 5 of 6 alleles, but not with mismatches at both alleles of a single locus (e.g.
not mismatched for both HLA A alleles).
|
Cord blood will be thawed (and processed if ABO incompatibility) per institutional SOP.
Other Names:
|
Other: haplo BM with T cell depletion
If there is no unrelated donor available meeting the matching criteria for unrelated bone marrow or unrelated cord blood donors.
|
haplo-identical (parental) bone marrow will be processed for CD34+ cell isolation.
Other Names:
|
Other: unrelated PBSC with T cell depletion
The preferred source will be bone marrow, however, if a donor is unable or unwilling to donate bone marrow, peripheral blood stem cells (PBSC) will be allowed.
|
peripheral blood stem cell will be processed for CD34+ cell isolation.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Engraftment
Time Frame: 100 day
|
Engraftment is defined as recovery of blood counts (neutrophil and platelet engraftment) with cells of donor origin, documented by either bone marrow or peripheral blood chimerism assays after hematopoietic stem cell transplant.
|
100 day
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Donor-derived CD3+ T Lymphocytes >/= 100/mm3
Time Frame: 1 year
|
Absolute number of donor-derived CD3+ T lymphocytes >/= 100/mm3 in participating subjects.
|
1 year
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Veno-occlusive Disease (VOD) - Moderate and Severe
Time Frame: 100 days
|
Evaluation of veno-occlusive disease determined by the presence of the following features; fluid retention, weight gain, leaky capillary syndrome, painful liver enlargement, refractoriness to platelet tranfusion and hyperbilirubinemia
|
100 days
|
Number of Participants With Graft Versus Host Disease (GVHD) - Grade III or IV
Time Frame: 1 year
|
GVHD disease surveillance done by clinical evaluation, to include history, physical examination, specifically for rash, jaundice, liver dysfunction, nausea and vomiting, diarrhea and failure to thrive.
|
1 year
|
Overall Survival
Time Frame: 1 year
|
Overalls survival of patient at 1 year post transplant
|
1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Neena Kapoor, M.D., Children's Hospital Los Angeles, University of Southern California
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CCI-06-00243
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Severe Combined Immunodeficiency
-
Great Ormond Street Hospital for Children NHS Foundation...UnknownX-linked Severe Combined ImmunodeficiencyUnited Kingdom
-
National Institute of Allergy and Infectious Diseases...RecruitingX-linked Severe Combined Immunodeficiency (XSCID)United States
-
St. Jude Children's Research HospitalNational Heart, Lung, and Blood Institute (NHLBI); Assisi Foundation; California...SuspendedSevere Combined Immunodeficiency Disease, X-linkedUnited States
-
Assistance Publique - Hôpitaux de ParisCompletedX-linked Severe Combined ImmunodeficiencyFrance
-
Shenzhen Geno-Immune Medical InstituteUnknownAdenosine DeAminase Severe Combined ImmunoDeficiency (ADA-SCID)China
-
David WilliamsActive, not recruitingGene Therapy | Severe Combined Immunodeficiency, X LinkedUnited States, United Kingdom
-
National Institute of Allergy and Infectious Diseases...TerminatedGrowth Failure | X-linked Severe Combined Immunodeficiency (XSCID) | Growth Hormone ResistenceUnited States
-
Great Ormond Street Hospital for Children NHS Foundation...RecruitingSevere Combined Immunodeficiency, X-LinkedUnited Kingdom
-
National Institute of Allergy and Infectious Diseases...UnknownX-Linked Combined Immunodeficiency DiseasesUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedSevere Combined ImmunodeficiencyUnited States
Clinical Trials on unrelated BM with T cell depletion
-
University of ChicagoRecruitingSickle Cell DiseaseUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)National Cancer Institute (NCI); Blood and Marrow Transplant Clinical Trials...CompletedLeukemia, Myelocytic, AcuteUnited States
-
Wake Forest University Health SciencesTerminatedAcute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Chronic Myeloid Leukemia | Myelodysplastic Syndrome | Immune Deficiency | Lymphomas | Bone Marrow Failure | Osteopetrosis | HemoglobinopathyUnited States
-
University of Alabama at BirminghamMiltenyi Biotec, Inc.Active, not recruitingHematopoietic Stem Cell TransplantationUnited States
-
Radboud University Medical CenterTerminatedLymphoma | Leukemia, Myeloid | Myelodysplastic Syndrome | Leukemia, Lymphocytic | Leukemia, Myeloid, ChronicNetherlands
-
Rajni AgarwalCompletedMalignant Diseases | Non-malignant DiseasesUnited States
-
Julie-An M. TalanoMiltenyi Biotec, Inc.Active, not recruitingHematologic MalignanciesUnited States
-
Federal Research Institute of Pediatric Hematology...CompletedPrimary Immune Deficiency Disorder | Hematopoietic Stem Cell TransplantationRussian Federation
-
Children's Hospital of PhiladelphiaCompletedImmunodeficienciesUnited States
-
Mariella EnocCompletedMyelodysplastic Syndromes | Acute Lymphoblastic Leukemia | Non-Hodgkin Lymphoma | Leukemia Acute Myeloid - AMLItaly